CA2934958A1 - Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy - Google Patents

Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy Download PDF

Info

Publication number
CA2934958A1
CA2934958A1 CA2934958A CA2934958A CA2934958A1 CA 2934958 A1 CA2934958 A1 CA 2934958A1 CA 2934958 A CA2934958 A CA 2934958A CA 2934958 A CA2934958 A CA 2934958A CA 2934958 A1 CA2934958 A1 CA 2934958A1
Authority
CA
Canada
Prior art keywords
vaccine
cancer
subject
biological sample
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2934958A
Other languages
English (en)
French (fr)
Inventor
Ross Arthur DAVEY
Christopher John WEIR
Graham Vesey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northern Sydney Local Health District
Cell Ideas Pty Ltd
Original Assignee
Northern Sydney Local Health District
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905669A external-priority patent/AU2012905669A0/en
Priority claimed from AU2013203806A external-priority patent/AU2013203806B2/en
Application filed by Northern Sydney Local Health District, Cell Ideas Pty Ltd filed Critical Northern Sydney Local Health District
Publication of CA2934958A1 publication Critical patent/CA2934958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA2934958A 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy Abandoned CA2934958A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2012905669A AU2012905669A0 (en) 2012-12-24 Vaccine booster
AU2012905667 2012-12-24
AU2012905667A AU2012905667A0 (en) 2012-12-24 Vaccines for treatment of cancer
AU2012905669 2012-12-24
AU2013203806A AU2013203806B2 (en) 2012-12-24 2013-04-11 Vaccines for the treatment or prevention of cancer
AU2013203806 2013-04-11
AU2013903592 2013-09-18
AU2013903592A AU2013903592A0 (en) 2013-09-18 Vaccines for the treatment or prevention of cancer
PCT/AU2013/001523 WO2014100857A1 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Publications (1)

Publication Number Publication Date
CA2934958A1 true CA2934958A1 (en) 2014-07-03

Family

ID=53547734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934958A Abandoned CA2934958A1 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Country Status (7)

Country Link
US (2) US10357538B2 (enExample)
EP (2) EP3446708A1 (enExample)
JP (2) JP6286445B2 (enExample)
AU (1) AU2013370932B2 (enExample)
CA (1) CA2934958A1 (enExample)
NZ (1) NZ629700A (enExample)
WO (1) WO2014100857A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3446708A1 (en) * 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
SG11201806587RA (en) 2016-02-04 2018-09-27 Longeveron Llc Mesenchymal stem cells as vaccine adjuvants and methods for using the same
JP6971986B2 (ja) * 2016-04-01 2021-11-24 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
US11054389B2 (en) * 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221636A (ja) * 1986-03-20 1987-09-29 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6379671B1 (en) * 1996-08-19 2002-04-30 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2302339A1 (en) 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20040076622A1 (en) * 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
AU2004268497A1 (en) * 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
AU2003903317A0 (en) 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
CN1887296B (zh) * 2006-07-31 2011-05-25 南京大学生物制药工程研究中心 一种诱导抗肿瘤免疫的方法及其在制药中的应用
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
US8771705B2 (en) 2009-07-30 2014-07-08 Healthbanks Biotech Co., Ltd. Combination of protein vaccine and mesenchymal stem cells for treating cancer
KR20110038569A (ko) * 2009-10-08 2011-04-14 주식회사 알앤엘바이오 인간 유래 성체 줄기세포를 함유하는 항암용 조성물
JP2013510582A (ja) * 2009-11-12 2013-03-28 ザ テキサス エーアンドエム ユニバーシティー システム 間葉幹細胞の球状集合体
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
EP3446708A1 (en) * 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Also Published As

Publication number Publication date
EP2934578A1 (en) 2015-10-28
AU2013370932A1 (en) 2015-07-09
EP2934578A4 (en) 2016-07-13
US10357538B2 (en) 2019-07-23
WO2014100857A1 (en) 2014-07-03
WO2014100857A8 (en) 2014-11-06
US20150343040A1 (en) 2015-12-03
WO2014100857A9 (en) 2015-07-09
EP3446708A1 (en) 2019-02-27
AU2013370932B2 (en) 2019-02-21
JP2016505003A (ja) 2016-02-18
JP2018111695A (ja) 2018-07-19
US20190358291A1 (en) 2019-11-28
EP2934578B1 (en) 2018-11-21
JP6286445B2 (ja) 2018-02-28
NZ629700A (en) 2017-01-27

Similar Documents

Publication Publication Date Title
US20190358291A1 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
AU2021203382B2 (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
JP6788663B2 (ja) 癌処置のための天然痘ワクチン
RU2766457C2 (ru) Способы и композиции для лечения рака с помощью антисмысла
US20220213440A1 (en) Dendritic cell immunotherapy
Muragaki et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma
EP3784220A1 (en) Edible plant exosome-like nanovectors for vaccination
Du et al. Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
BR112012019267B1 (pt) Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula
WO2017193862A1 (zh) Fats作为黑色素瘤免疫治疗的靶点及应用
Mocan et al. RETRACTED ARTICLE: Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes
CN113244273A (zh) 疟原虫在制备联合放射疗法用于抗肿瘤的制剂中的应用
Chen et al. Antigen-caged-adjuvant nanovaccines elicit potent humoral and cellular immune responses
CN109891238A (zh) 免疫治疗剂的剂量确定
AU2013203806B2 (en) Vaccines for the treatment or prevention of cancer
CN104042628B (zh) 氢氧化铝在制备治疗肝癌药物中的应用
CN107174657A (zh) 制备靶向胶质瘤和胶质瘤干细胞的抗原组合物的方法以及含有该抗原组合物的疫苗
WO2007043630A1 (ja) 上気道粘膜下に投与されるｎｋｔ細胞刺激剤
CN109045288A (zh) FGFR1-MIP3α/Fc融合蛋白在制备靶向抗乳腺癌药物中的用途
ES2791410T3 (es) Uso de composiciones inmunomoduladoras eficaces para el tratamiento inmunoterápico de pacientes que padecen leucemias mielógenas
CN120676961A (zh) 基于γ-δT细胞细胞外囊泡的肿瘤疫苗的组合物和方法
WO2025217985A1 (zh) 葡萄糖-1-磷酸在治疗肿瘤中的用途
JP2023119754A (ja) カクテル樹状細胞ワクチンの製造方法
CN116769709A (zh) 裂解液在制备囊泡中的应用
CN120392969A (zh) 免疫联合用药物及其在治疗肿瘤中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181217

FZDE Discontinued

Effective date: 20210831